eligibility_summary
Eligible participants are individuals who consent to long-term follow-up and have previously received at least one infusion of Inaticabtagene Autoleucel, either as part of a registered clinical trial (any indication) or post-market use. No exclusion criteria specified.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Inaticabtagene autoleucel (CNCT19) — an autologous, gene‑modified CAR‑T cell therapy. Mechanism: patients’ T cells are engineered to express a chimeric antigen receptor that binds CD19 on B cells, CAR signaling (CD3ζ with costimulation) activates T‑cell cytotoxicity and cytokine release, eliminating CD19+ malignant B cells and causing on‑target B‑cell depletion. Targets: CD19 antigen on B‑cell tumors, effector pathways include CAR‑triggered T‑cell activation, perforin/granzyme‑mediated killing, and inflammatory cytokine signaling. Study: 15‑year observational LTFU for late AEs in China.